# EDGAR Filing Document

**Accession Number:** 0002104204
**File Stem:** 0001193125-26-159789
**Filing Date:** 2026-4
**Character Count:** 16964
**Document Hash:** f6b345e97cff696d76f174a080611acb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-159789.hdr.sgml**: 20260416

**ACCESSION NUMBER**: 0001193125-26-159789

**CONFORMED SUBMISSION TYPE**: S-1MEF

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20260416

**DATE AS OF CHANGE**: 20260416

**EFFECTIVENESS DATE**: 20260416

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Alamar Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0002104204
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 364899036
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-1MEF
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-295116
- **FILM NUMBER:** 26869084

**BUSINESS ADDRESS:**
- **STREET 1:** 47071 BAYSIDE PARKWAY
- **CITY:** FREMONT
- **STATE:** CA
- **ZIP:** 94538
- **BUSINESS PHONE:** 510-626-9888

**MAIL ADDRESS:**
- **STREET 1:** 47071 BAYSIDE PARKWAY
- **CITY:** FREMONT
- **STATE:** CA
- **ZIP:** 94538

**As filed with the Securities and Exchange Commission on April 16, 2026.** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-1** 

**REGISTRATION STATEMENT** 

***Under***

***The Securities Act of 1933***

## Alamar Biosciences, Inc.
**(Exact name of registrant as specified in its charter)** 

---

| | | |
|:---|:---|:---|
| **Delaware** | **3826** | **36-4899036** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(Primary Standard Industrial**<br> **Classification Code Number)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

**47071 Bayside Parkway** 

**Fremont, California 94538** 

**(510) 626-9888**

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)** 

**Yuling Luo, Ph.D.** 

**Founder, Chairman and Chief Executive Officer** 

**Alamar Biosciences, Inc.** 

**47071 Bayside Parkway** 

**Fremont, California 94538** 

**(510) 626-9888** 

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

***Copies to:***

---

| | | |
|:---|:---|:---|
| **Kristin VanderPas**<br> **Charles S. Kim**<br> **Dave Peinsipp**<br> **Cooley LLP**<br> **3 Embarcadero Center**<br> **20th Floor**<br> **San Francisco, California 94111**<br> **(415) 693-2000** | **Timothy "Tod" White**<br> **President**<br> **47071 Bayside Parkway**<br> **Fremont, California 94538**<br> **(510) 626-9888** | **Nathan Ajiashvili**<br> **Ross McAloon**<br> **B. Shayne Kennedy**<br> **Latham & Watkins LLP**<br> **1271 Avenue of the Americas**<br> **New York, New York 10020**<br> **(212) 906-1200** |

---

**Approximate date of commencement of proposed sale to the public:** As soon as practicable after this Registration Statement becomes effective.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box: ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ (333-294697)

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**The Registration Statement shall become effective upon filing in accordance with Rule 462(b) promulgated under the Securities Act of 1933, as amended.** 

------

**EXPLANATORY NOTE AND INCORPORATION BY REFERENCE** 

This Registration Statement is being filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the "Securities Act"), by Alamar Biosciences, Inc. (the "Registrant"), for the sole purpose of increasing the aggregate number of shares of common stock offered and registered by the Earlier Registration Statement (as defined below) by 2,156,250 shares, 281,250 of which are subject to purchase upon exercise of the underwriters' option to purchase additional shares of the Registrant's common stock. The contents of the Registration Statement on Form S-1, as amended (File No. 333-294697), including all exhibits thereto (the "Earlier Registration Statement"), filed by the Registrant with the Securities and Exchange Commission (the "Commission") pursuant to the Securities Act, which was declared effective by the Commission on April 16, 2026, are incorporated by reference into this Registration Statement. The additional shares of common stock that are being registered for issuance and sale pursuant to this Registration Statement are in an amount and at a price that together represent no more than 20% of the maximum aggregate offering price set forth in Exhibit 107 of the Earlier Registration Statement.

The required opinion and consents are listed on an Exhibit Index attached hereto and filed herewith.

**EXHIBIT INDEX** 

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Description** |
| 5.1 | [Opinion of Cooley LLP.](d620616dex51.htm) |
| 23.1 | [Consent of Independent Registered Public Accounting Firm.](d620616dex231.htm) |
| 23.4 | [Consent of Cooley LLP (included in Exhibit 5.1).](d620616dex51.htm) |
| 24.1\* | [Power of Attorney.](http://www.sec.gov/Archives/edgar/data/2104204/000119312526129039/d39680ds1.htm#sig) |
| 107 | [Filing Fee Table.](d620616dexfilingfees.htm) |

---

\* Previously filed on the signature page to the Registrant's Registration Statement on Form S-1 (File No. 333-294697), originally filed with the Securities and Exchange Commission on March 27, 2026 and incorporated by reference herein.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Fremont, State of California on April 16, 2026.

---

| | |
|:---|:---|
| **ALAMAR BIOSCIENCES, INC.** | **ALAMAR BIOSCIENCES, INC.** |
| By: | /s/ Yuling Luo, Ph.D. |
|  | Yuling Luo, Ph.D. |
|  | Chief Executive Officer |

---

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement on Form S-1 has been signed by the following persons in the capacities held on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Yuling Luo, Ph.D.<br> Yuling Luo, Ph.D. | Chief Executive Officer and Director<br> (*Principal Executive Officer*) | April 16, 2026 |
| /s/ Justin McAnear<br> Justin McAnear | Chief Financial Officer<br> (*Principal Financial and Accounting Officer*) | April 16, 2026 |
| \*<br> Rebecca Chambers | Director | April 16, 2026 |
| \*<br> Shiping Chen, Ph.D. | Director | April 16, 2026 |
| \*<br> Nicholas Naclerio, Ph.D. | Director | April 16, 2026 |
| \*<br> Ian Ratcliffe | Director | April 16, 2026 |
| \*<br> Frank R. Witney | Director | April 16, 2026 |

---

---

| | |
|:---|:---|
| \*By: | /s/ Yuling Luo, Ph.D. |
|  | Yuling Luo, Ph.D. |
|  | Attorney-in-Fact |

---

## Exhibit 5.1

**Exhibit 5.1**![LOGO](g620616g0416132918660.jpg)

David Peinsipp

+1 (415) 693-2177

dpeinsipp@cooley.com

April 16, 2026

Alamar Biosciences, Inc.

47071 Bayside Pkwy

Fremont, CA 94538

Ladies and Gentlemen:

We have acted as counsel to Alamar Biosciences, Inc., a Delaware corporation (the "***Company***"), in connection with the filing by the Company of a registration statement on Form S-1 (the "***Registration Statement***") with the Securities and Exchange Commission (the "***Commission***") pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the "***Securities Act***"), covering an underwritten public offering of up to 2,156,250 of the Company's common stock, par value $0.0001 per share ("***Shares***"). The Registration Statement incorporates by reference the registration statement on Form S-1, as amended (No. 333-294697) (the "***Prior Registration Statement***"), including the prospectus that is part of the Prior Registration Statement (the "***Prospectus***").

In connection with this opinion, we have (i) examined and relied upon (a) the Registration Statement and the Prospectus, (b) the Company's certificate of incorporation and bylaws, each as currently in effect, (c) the Company's Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, filed as 3.2 and Exhibit 3.4 to the Prior Registration Statement, respectively, each of which is to be in effect in connection with the closing of the offering contemplated by the Prior Registration Statement, and (d) such other records, documents, opinions, certificates, memoranda and instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below and (ii) the Amended and Restated Certificate of Incorporation referred to in clause (i)(c) is filed with the Secretary of State of the State of Delaware before issuance of the Shares.

We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials and the due authorization, execution and delivery of all documents by all persons other than the Company. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, in reliance thereon and subject to the assumptions, qualifications, limitations and exceptions set forth here, we are of the opinion that the Shares, when sold and issued against payment therefor as described in the Prior Registration Statement and the Prospectus, will be validly issued, fully paid and nonassessable.

This opinion is limited to the matters expressly set forth in this letter, and no opinion should be implied, or may be inferred, beyond the matters expressly stated. This opinion speaks only as to law and facts in effect or existing as of the date hereof and we have no obligation or responsibility to update or supplement this letter to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may hereafter occur.

Cooley LLP 3 Embarcadero Center, 20th Floor, San Francisco, CA 94111-4004

t: +1 (415) 693-2000 f: +1 (415) 693-2222 cooley.com

------

![LOGO](g620616g0416132918660.jpg)

Alamar Biosciences, Inc.

We consent to the reference to our firm under the caption "Legal Matters" in the Prospectus included in the Prior Registration Statement and to the filing of this opinion as an exhibit to the Registration Statement. In giving such consents, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission thereunder.

---

| | |
|:---|:---|
| Sincerely, | Sincerely, |
| Cooley LLP | Cooley LLP |
| By: | /s/ *David Peinsipp* |
|  | David Peinsipp |

---

Cooley LLP 3 Embarcadero Center, 20th Floor, San Francisco, CA 94111-4004

t: +1 (415) 693-2000 f: +1 (415) 693-2222 cooley.com

## Exhibit 23.1

**Exhibit 23.1** 

**Consent of Independent Registered Public Accounting Firm** 

We consent to the incorporation by reference in the Registration Statement on Form S-1 filed pursuant to Rule 462(b) of the Securities Act of 1933 of the reference to our firm under the caption "Experts" and to the incorporation by reference of our report dated March 12, 2026 (except for the effects of the reverse stock split described in Note 17, as to which the date is April 13, 2026), with respect to the consolidated financial statements of Alamar Biosciences, Inc. included in Amendment No. 2 to the Registration Statement (Form S-1 No. 333-294697) and related Prospectus of Alamar Biosciences, Inc. for the registration of its common stock.

/s/ Ernst & Young LLP

San Jose, California

April 16, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-1**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Alamar Biosciences, Inc.**  |

---

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | | **Security Type**  | **Security Class Title**  | **Fee Calculation or Carry Forward Rule**  | **Amount Registered**  | **Proposed Maximum Offering Price Per Unit**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** |
| Fees to be Paid | 1 | Equity | Common Stock, $0.0001 par value per share | 457(a) | 2156250 | $17.00 | $36656250.00 | 0.0001381 | $5062.23 |
| Fees Previously Paid |  |  |  |  |  |  |  |  |  |
| **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** |
| Carry Forward Securities |  |  |  |  |  |  |  |  |  |
|  |  |  | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $36656250.00  |  | $5062.23  |
|  |  |  | Total Fees Previously Paid:  | Total Fees Previously Paid:  | Total Fees Previously Paid:  |  |  |  | $0.00  |
|  |  |  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
|  |  |  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $5062.23  |

---

 **Offering Note** <br>

<sup>1</sup> (1) Represents only the additional number of shares being registered and includes 281,250 shares of common stock issuable upon exercise of the underwriters' option to purchase additional shares. Does not include the securities that the Registrant previously registered on the Registration Statement on Form S-1 (File No. 333-294697), as amended (the "Earlier Registration Statement"). (2) Based on the public offering price. (3) The registration fee is calculated in accordance with Rule 457(a) under the Securities Act of 1933, as amended, based on the proposed maximum aggregate offering price. The registrant previously registered securities on the Earlier Registration Statement having a proposed maximum aggregate offering price of $183,281,250.00, which was declared effective by the Securities and Exchange Commission on April 16, 2026. In accordance with Rule 462(b) under the Securities Act, an additional amount of securities having a proposed maximum aggregate offering price of $36,656,250.00 is hereby registered, which includes shares issuable upon the exercise of the underwriters' option to purchase additional shares.

---

| |
|:---|
| |
| **Rules 457(b) and 0-11(a)(2)** |
| Fee Offset Claims |
| Fee Offset Sources |
| **Rule 457(p)** |
| Fee Offset Claims |
| Fee Offset Sources |

---